{
  "image_filename": "table_p4_det_3_003.png",
  "image_path": "Zimmerman_et_al.__2023_/extracted/figures/table_p4_det_3_003.png",
  "image_type": "Table",
  "page_number": 4,
  "block_id": "det_3_003",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "A table of baseline measures (race, sex, season, age group, influenza case status, high-risk condition) comparing two vaccine groups labeled \u2018Received RIV4\u2019 (n=3,338) and \u2018Received SD-IIV4\u2019 (n=976) with P-values for differences The table does not mention Flublok or Fluarix by name and does not describe a pivotal trial comparing Flublok (quadrivalent) against Fluarix (quadrivalent standard-dose vaccine), so it does not support the claim Note: Limited to the visible table; vaccine brands and trial context are not specified",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table of baseline measures (race, sex, season, age group, influenza case status, high-risk condition) comparing two vaccine groups labeled \u2018Received RIV4\u2019 (n=3,338) and \u2018Received SD-IIV4\u2019 (n=976) with P-values for differences",
    "evidence_found": null,
    "reasoning": "The table does not mention Flublok or Fluarix by name and does not describe a pivotal trial comparing Flublok (quadrivalent) against Fluarix (quadrivalent standard-dose vaccine), so it does not support the claim",
    "confidence_notes": "Limited to the visible table; vaccine brands and trial context are not specified"
  }
}